The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index; 158 of the 216 sources its claims cite were checked for support.
A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease
Open accessAbstract
Arrhythmogenic cardiomyopathy (ACM) is a genetic myocardial disorder marked by progressive cardiomyocyte loss, fibro-fatty replacement, ventricular arrhythmias, and risk of sudden cardiac death. Traditionally considered a structural and electrical disease driven by desmosomal dysfunction, emerging evidence redefines ACM as an inflammatory cardiomyopathy in which immune activation plays a central role. This review integrates genetic, molecular, experimental, and clinical data to highlight inflammation as a unifying feature of ACM. Desmosomal gene variants impair cell adhesion and also activate cardiomyocyte-intrinsic inflammatory pathways, including nuclear factor of kappa B (NFκB) and glycogen synthase kinase 3β (GSK3β) signaling, promoting cytokine release, immune cell recruitment, and fibrotic remodeling. Preclinical studies suggest inflammation precedes structural changes, indicating it may be an initiating event rather than a secondary response. Clinical and pathological findings support this model, with inflammatory infiltrates, circulating cytokines, and autoantibodies observed across disease stages. These processes often present as episodic "hot phases" resembling myocarditis, thus complicating diagnosis. The inflammatory landscape involves both innate and adaptive immunity, along with stromal and neuronal remodeling, contributing to arrhythmogenesis through gap junction disruption, calcium-handling abnormalities, and fibrosis. Environmental factors such as exercise, stress, and metabolic disturbances further modulate inflammatory pathways and disease expression. Therapeutically, this evolving perspective supports immunomodulatory approaches, including inhibition of NFκB, GSK3β, and cytokine signaling. Early clinical data on immunosuppressive and cytokine-directed therapies are promising, especially during active inflammatory phases, while gene-based strategies specifically address the underlying genetic defects. In conclusion, ACM should be recognized as an inflammatory cardiomyopathy shaped by interactions between genetic susceptibility and immune dysregulation. Integrating genetic and immunologic profiling may improve diagnosis, risk stratification, and treatment, ultimately leading to refined personalized therapeutic strategies.
Overview
CoChat Summary
## TL;DR
This narrative review argues that arrhythmogenic cardiomyopathy (ACM) should be understood as an inflammatory cardiomyopathy, not only a desmosomal structural/electrical disorder. It synthesizes clinical, pathological, experimental, and early therapeutic evidence showing that inflammation can precede remodeling and may be a treatment target.
## Key findings
- Desmosomal gene variants account for more than 60% of patient cases, and inflammatory infiltrates are reported in 60–88% of ACM patients, especially those who died suddenly.
- The review states that myocardial inflammation often appears as a “hot phase,” with features that can mimic myocarditis, including chest pain, recurrent troponin peaks, and LGE-MRI abnormalities; DGV-positive patients with myocarditis-like phenotypes are at increased risk of major ventricular arrhythmias and heart failure.
- In preclinical models, inflammatory signaling is described as an early event: snRNA-seq and other multi-omic analyses showed cardiomyocyte-intrinsic NFκB activation, recruitment of CCR2+ macrophages, and inflammatory-fibrotic niche formation before extensive fibrosis.
- Therapeutic examples reported include SB216763 improving ventricular ectopy, function, fibrosis, inflammation, normalization of ID proteins, and survival in two murine ACM models, and Tideglusib being evaluated in a Phase 2 TaRGET clinical trial.
## Methods
- Narrative review of ACM literature integrating genetic, molecular, experimental, and clinical evidence.
- The authors report searching PubMed for original clinical and preclinical papers using the keywords “ACM”, “inflammation” and “immunity.”
- The review synthesizes findings from in vivo and in vitro models, human biopsies, snRNAseq, CITE-seq/CITseq, spatial transcriptomics, imaging, and interventional studies.
## Limitations
- The paper states that myocardial inflammation is not homogeneously detected in all preclinical models and patients with ACM.
- The authors note that several other molecular mechanisms contribute to ACM onset and progression, so inflammation is not the only pathway.
- The text says prospective trials are still needed to formally assess the safety and efficacy of immunosuppressive and molecularly targeted therapies; this is evident from the review nature of the paper and the reliance on preclinical/early clinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
106 Valid · 4 Not valid · 21 Not checked · 38 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“growing evidence implicates immune-mediated inflammatory mechanisms in disease onset and progression [11,12].”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation source
The Introduction (page not supplied) says that inflammatory cells and an innate immune response in cardiac myocytes could contribute to ACM onset and progression. The Discussion adds evidence that inflammatory signaling is involved in ACM pathogenesis, matching the claim’s cautious wording. (LLM, conf=0.93)
- Supportedcites [12] Chelko, 2024, NFκB Signaling Drives Myocardial Injury via CCR2+ Macrophages in a Preclinical Model of Arrhythmogenic Cardiomyopathy, J. Clin. Investig. source
The Introduction states that growing evidence implicates inflammation in ACM pathogenesis. The Discussion reports that blocking NFκB signaling in cardiac myocytes attenuated disease in an ACM mouse model, supporting the claim that immune-mediated mechanisms contribute to disease progression. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prior works have shown elevated levels of circulating [22] and myocardial inflammatory cytokines and chemokines from DGV-linked ACM subjects [11,23] that have been observed across disease phases and phenotypes”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Partly supportedcites [22] Asimaki, 2011, Altered Desmosomal Proteins in Granulomatous Myocarditis and Potential Pathogenic Links to Arrhythmogenic Right Ventricular Cardiomyopathy, Circ. Arrhythm. Electrophysiol. sourceExperimental — accuracy not yet measured
The Results section, “Myocardial expression of cytokines in ARVC” (page unavailable), reports increased myocardial IL-17 and TNFα signals in ARVC cases, including five with documented desmosomal gene mutations. It does not establish that these elevations occur across disease phases or phenotypes. The paper also reports elevated circulating inflammatory mediators, but the citing sentence assigns the circulating finding to a different citation [22]. (LLM, conf=0.86)
- Partly supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation sourceExperimental — accuracy not yet measured
The Results section on cytokine production reports elevated inflammatory cytokines and chemokines in hearts of Dsg2-mutant ACM mice; the patient-derived cells studied were cultured cardiomyocytes, not myocardial samples. The paper does not establish that myocardial elevations occur in ACM subjects across disease phases and phenotypes. The circulating-level claim is attached to a different citation. (LLM, conf=0.87)
- Partly supportedcites [23] Hawthorne, R.N., Blazeski, A., Lowenthal, J., Kannan, S., Teuben, R., Disilvestre, D., Morrissette-Mcalmon, J., Saffitz, J.E., Boheler, K.R., and James, C.A. (2021). Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. J. Clin. Med., 10. sourceExperimental — accuracy not yet measured
Results §3.4 reports elevated inflammatory cytokines and chemokines in DSG2-mutant patient-derived cardiomyocytes and notes a prior finding in Dsg2-mutant mouse myocardium. It does not establish elevated levels in myocardial samples from human subjects across disease phases and phenotypes. The circulating-level claim is attached to a different citation in the citing sentence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent works have demonstrated CCR2+ macrophages are early and persistent drivers of cardiac inflammation in ACM [12].”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 2. Race to Discovery: Myocardial Inflammation as a Key Pathological Phenotype in ACM
What the sources say
- Partly supportedcites [12] Chelko, 2024, NFκB Signaling Drives Myocardial Injury via CCR2+ Macrophages in a Preclinical Model of Arrhythmogenic Cardiomyopathy, J. Clin. Investig. sourceExperimental — accuracy not yet measured
The Results section reports increased CCR2+ macrophages at 4, 6, 10, and 16 weeks in Dsg2mut/mut mouse hearts, and identifies CCR2+ monocytes and macrophages as a primary source of inflammatory mediators. This supports an early, sustained inflammatory role in that preclinical model, but the paper does not establish that CCR2+ macrophages are early and persistent drivers across patients with ACM. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“environmental modifiers such as endurance exercise [24,25,26,27,28,29,30], psychological stress [31,32,33], diet [34,35], alcohol [36], and metabolic dysregulation [37,38,39] have been shown to influence disease penetrance and progression, in part, through modulation of inflammatory processes.”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [24] Sawant, 2016, Safety of American Heart Association-Recommended Minimum Exercise for Desmosomal Mutation Carriers, Heart Rhythm source
- Not checked — no full text of the sourcecites [25] Jacobsen, 2025, Endurance Exercise Promotes Episodes of Myocardial Injury in Individuals with a Pathogenic Desmoplakin (DSP) Variant, Heart Rhythm source
- Partly supportedcites [26] James, 2013, Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy-Associated Desmosomal Mutation Carriers, J. Am. Coll. Cardiol. sourceExperimental — accuracy not yet measured
The Discussion sections on clinical course and the relationship between exercise and ARVD/C report that endurance exercise is associated with greater disease penetrance and worse outcomes in desmosomal mutation carriers. The proposed inflammatory mechanism is less certain: the paper says exercise “may facilitate” myocyte uncoupling leading to inflammation, rather than showing that modulation of inflammation mediates those outcomes. This citation is attached to endurance exercise, not the other modifiers listed in the sentence. (LLM, conf=0.85)
- Partly supportedcites [27] Sawant, 2014, Exercise Has a Disproportionate Role in the Pathogenesis of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in Patients without Desmosomal Mutations, J. Am. Heart Assoc. sourceExperimental — accuracy not yet measured
The Discussion (Main Findings; Study Findings) reports that intense endurance exercise is associated with earlier presentation, worse structural disease, and a more aggressive arrhythmic course in gene-elusive ARVD/C. The citation is attached to endurance exercise, not the other listed modifiers. Our copy does not establish that exercise acts through modulation of inflammatory processes. (LLM, conf=0.85)
- Not checked yetcites [28] Bosman, 2022, Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy, Circ. Arrhythm. Electrophysiol. source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [29] Chelko, 2021, Exercise Triggers CAPN1-Mediated AIF Truncation, Inducing Myocyte Cell Death in Arrhythmogenic Cardiomyopathy, Sci. Transl. Med. sourceExperimental — accuracy not yet measured
The Discussion states that exercise can increase the risk of ACM progression, and the Results report prominent myocardial inflammation and immune-cell infiltration in exercised ACM-model mice (page numbers unavailable). The paper does not establish that inflammation mediates exercise’s effect on progression or demonstrate an effect on disease penetrance. The other listed modifiers have separate citations and are not assessed here. (LLM, conf=0.84)
- Not checked yetcites [30] Cerrone, 2022, Role of Plakophilin-2 Expression on Exercise-Related Progression of Arrhythmogenic Right Ventricular Cardiomyopathy: A Translational Study, Eur. Heart J. source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [31] Agrimi, J., Scalco, A., Agafonova, J., Williams, L., Pansari, N., Keceli, G., Jun, S., Wang, N., Mastorci, F., and Tichnell, C. (2020). Psychosocial Stress Hastens Disease Progression and Sudden Death in Mice with Arrhythmogenic Cardiomyopathy. J. Clin. Med., 9. sourceExperimental — accuracy not yet measured
The citation is attached to psychological stress, not to the separately cited modifiers. The Results report an association between perceived stress and ACM severity in patients, while the mouse findings support a role for psychosocial stress in disease progression. The Discussion mentions heightened sensitivity to pro-inflammatory disorders in stressed rodents, but does not establish that inflammation mediates ACM progression in this study. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [32] James, 2012, General and Disease-Specific Psychosocial Adjustment in Patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Implantable Cardioverter Defibrillators: A Large Cohort Study, Circ. Cardiovasc. Genet. source
- Could not verifycites [33] Singh, 2021, Anxiety and Depression in Inherited Channelopathy Patients with Implantable Cardioverter-Defibrillators, Heart Rhythm O2 sourceExperimental — accuracy not yet measured
The Discussion reports anxiety and depression in patients with inherited channelopathies and ICDs, but does not link psychological stress to ACM penetrance or progression. Searches for stress, inflammatory processes, and the other listed modifiers found no passage addressing the claimed mechanism. (LLM, conf=0.76)
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that inflammatory processes may represent more than just an epiphenomenon of immune cell-mediated cardiomyocyte injury.”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation source
The Discussion (page not provided) reports that ACM disease alleles activate an innate immune response in cardiac myocytes independently of inflammatory cells. It also suggests that signaling within those myocytes may drive key clinical features, supporting the claim that inflammation is more than a byproduct of immune cell-mediated injury. (LLM, conf=0.94)
- Supportedcites [23] Hawthorne, R.N., Blazeski, A., Lowenthal, J., Kannan, S., Teuben, R., Disilvestre, D., Morrissette-Mcalmon, J., Saffitz, J.E., Boheler, K.R., and James, C.A. (2021). Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. J. Clin. Med., 10. source
The Discussion reports an intrinsic inflammatory pathway in DSG2-mutant cardiomyocytes that is independent of immune-cell infiltration. It also suggests that this pathway may drive immune-cell recruitment, supporting the claim that inflammation may be more than a byproduct of immune-cell-mediated injury. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
69 more claims · 41 with their cited sources checked
Create a free account to see all 169 claims and to verify the 24 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 9
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Marcus, F. I., McKenna, W. J., Sherrill, D., Basso, C., Bauce, B., Bluemke, D. A., Calkins, H., Corrado, D., Cox, M. G. P. J., Daubert, J. P., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.840827 · Cited by 2,676
Right Ventricular Dysplasia: A Report of 24 Adult Cases
Marcus, F. I., Fontaine, G. H., Guiraudon, G., Frank, R., Laurenceau, J. L., Malergue, C., & Grosgogeat, Y. (1982) · Circulation · doi:10.1161/01.cir.65.2.384 · Cited by 1,603
Corrado, D., Basso, C., Pavei, A., Michieli, P., Schiavon, M., & Thiene, G. (2006) · JAMA · doi:10.1001/jama.296.13.1593 · Cited by 1,559
Corrado, D., Basso, C., Thiene, G., McKenna, W. J., Davies, M. J., Fontaliran, F., Nava, A., Silvestri, F., Blomstrom-Lundqvist, C., Wlodarska, E. K., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00332-x · Cited by 978
Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905 · cited 1×
“TGF-β 1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
Arrhythmogenic Right Ventricular Cardiomyopathy: Dysplasia, Dystrophy, or Myocarditis?
Basso, C., Thiene, G., Corrado, D., Angelini, A., Nava, A., & Valente, M. (1996) · Circulation · doi:10.1161/01.cir.94.5.983 · Cited by 890
Towbin, J. A., McKenna, W. J., Abrams, D. J., Ackerman, M. J., Calkins, H., Darrieux, F. C. C., Daubert, J. P., de Chillou, C., DePasquale, E. C., Desai, M. Y., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.05.007 · Cited by 846
James, C. A., Bhonsale, A., Tichnell, C., Murray, B., Russell, S. D., Tandri, H., Tedford, R. J., Judge, D. P., & Calkins, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.033 · Cited by 710
Garcia-Gras, E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27751 · Cited by 623
Cited by
Urbanowicz, T. K., & Filipiak, K. J. (2026) · Cells · doi:10.3390/cells15141308 · Cited by 1
Metadata
- Authors
- Ariyaratne, G. H. D. N., Villatore, A., Peretto, G., & Chelko, S. P.
- Affiliations
- Florida State University (US)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Chelko, Stephen P.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2026-05-09
- Volume
- 15
- Issue
- 10
- Pages
- 868
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC13204042
- OpenAlex
- W7162287531
- Cited by
- 2
- References
- 123
- Citations by year
- 2026: 2
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Florida Heart Research Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Keywords
- arrhythmogenic cardiomyopathy, inflammatory cardiomyopathy, immune activation, NF-κB signaling, GSK3β signaling, cytokines, autoantibodies, myocarditis, fibrosis, gap junctions, calcium handling, sudden cardiac death, immunomodulatory therapy, genetic susceptibility
- MeSH terms
- Animals, Arrhythmias, Cardiac, Desmosomes, Humans, Inflammation, Cardiomyopathies, Signal Transduction, Arrhythmogenic Right Ventricular Dysplasia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease. https://app.cochat.ai/papers/10.3390/cells15100868
- The paper
- Ariyaratne, G. H. D. N., Villatore, A., Peretto, G., & Chelko, S. P. (2026). A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease. Cells. https://doi.org/10.3390/cells15100868
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.